Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Patrizio Castagnola
Cooperative but Distinct Early Co-Signaling Events Originate From ERBB2 and ERBB1 Receptors Upon Trastuzumab Treatment in Breast Cancer Cells
Oncotarget
Oncology
Related publications
Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer
JAMA Oncology
Cancer Research
Oncology
Akt Rescue in Cardiomyocytes but Not Breast Cancer Cells After Doxorubicin and Anti-erbB2 Treatment
AKT Signaling in ERBB2-amplified Breast Cancer
Pharmacology and Therapeutics
Pharmacology
Combining Lapatinib (GW572016), a Small Molecule Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, With Therapeutic Anti-ErbB2 Antibodies Enhances Apoptosis of ErbB2-overexpressing Breast Cancer Cells
Oncogene
Cancer Research
Genetics
Molecular Biology
Combination Treatment With Grb7 Peptide and Doxorubicin or Trastuzumab (Herceptin) Results in Cooperative Cell Growth Inhibition in Breast Cancer Cells
British Journal of Cancer
Cancer Research
Oncology
Women With Early Breast Cancer to Be Tested for Trastuzumab Treatment
BMJ
Preexisting Oncogenic Events Impact Trastuzumab Sensitivity in ERBB2-amplified Gastroesophageal Adenocarcinoma
Journal of Clinical Investigation
Medicine
Trastuzumab-Related Cardiotoxicity in Early Breast Cancer: A Cohort Study
Oncologist
Cancer Research
Medicine
Oncology
T-Darpp Activates IGF-1R Signaling to Regulate Glucose Metabolism in Trastuzumab-Resistant Breast Cancer Cells
Clinical Cancer Research
Cancer Research
Oncology
